Advertisement
Advertisement
KRRO
Korro Bio, Inc. Common Stock
14.75
USDSponsored
+0.02
+0.14%
Nov 06, 15:59 UTC -5
Closed
After-Market
14.76
+0.01
+0.07%
Korro Bio, Inc. Common Stock (KRRO) Earnings
KRRO Earnings Reports
Positive Surprise Ratio
KRRO beat 17 of 29 last estimates.
59%
Next Report
Date of Next Report
Mar 10, 2027
Estimate for Q4 26 (Revenue/ EPS)
$1.75M
/-$1.39
Implied change from Q3 26 (Revenue/ EPS)
--
/+41.84%
Implied change from Q4 25 (Revenue/ EPS)
+35.28%
/-15.76%
Korro Bio, Inc. Common Stock earnings per share and revenue
On Nov 05, 2026, KRRO reported earnings of -0.98 USD per share (EPS) for Q3 26, beating the estimate of -1.28 USD, resulting in a 23.58% surprise. Revenue reached --, compared to an expected 170.00 thousand, with a -100.00% difference. The market reacted with a -11.37% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -1.39 USD, with revenue projected to reach 1.75 million USD, implying an increase of 41.84% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cronos Group Inc. Common Share
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.03
Actual
$0.04
Surprise
+17.65%
Aclaris Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.12
Surprise
+28.49%
Protara Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.35
Surprise
+6.17%
Minerva Neurosciences, Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.12
Actual
$1.94
Surprise
+1,629.97%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.25
Surprise
-40.06%
ZOETIS INC.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.52
Actual
$1.75
Surprise
+14.64%
Dyne Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.92
Actual
-$1.06
Surprise
-15.57%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.38
Surprise
+1.04%
Aldeyra Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+37.43%
Lipocine Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.36
Actual
-$0.08
Surprise
+77.91%
FAQ
What were Korro Bio, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Korro Bio, Inc. Common Stock reported EPS of -$0.98, beating estimates by 23.58%, and revenue of $0.00, -100% below expectations.
How did the market react to Korro Bio, Inc. Common Stock's Q3 2026 earnings?
The stock price moved down -11.37%, changed from $16.62 before the earnings release to $14.73 the day after.
When is Korro Bio, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 10, 2027.
What are the forecasts for Korro Bio, Inc. Common Stock's next earnings report?
Based on --
analysts, Korro Bio, Inc. Common Stock is expected to report EPS of -$1.39 and revenue of $1.75M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.